X
Single-Cell Omics: Volume 1: Technological Advances
Single-Cell Omics: Volume 1: Technological Advances
Single-Cell Omics: Volume 1: Technological Advances

Single-Cell Omics: Volume 1: Technological Advances and Applications

Product ID : 48919175


Galleon Product ID 48919175
Shipping Weight 2.11 lbs
I think this is wrong?
Model
Manufacturer Academic Press
Shipping Dimension 9.25 x 7.56 x 0.98 inches
I think this is wrong?
-
No price yet.
Price not yet available.

Pay with

About Single-Cell Omics: Volume 1: Technological Advances

Product Description Single-Cell Omics: Volume 1: Technological Advances and Applications provides the latest technological developments and applications of single-cell technologies in the field of biomedicine. In the current era of precision medicine, the single-cell omics technology is highly promising due to its potential in diagnosis, prognosis and therapeutics. Sections in the book cover single-cell omics research and applications, diverse technologies applied in the topic, such as pangenomics, metabolomics, and multi-omics of single cells, data analysis, and several applications of single-cell omics within the biomedical field, for example in cancer, metabolic and neuro diseases, immunology, pharmacogenomics, personalized medicine and reproductive health. This book is a valuable source for bioinformaticians, molecular diagnostic researchers, clinicians and members of the biomedical field who are interested in understanding more about single-cell omics and its potential for research and diagnosis. Review Presents the latest technological developments and the applications of single-cell technologies in the field of biomedicine About the Author Dr. Debmalya Barh is the Founder and Principal Scientist of Institute of Integrative Omics and Applied Biotechnology (IIOAB), INDIA. He is having 15+ years leading academic, healthcare, molecular diagnostic, and bioinformatics industry experience and an expert in integrative omics-based biomarkers, targets and targeted drug discovery, and personalized medicine in cancers and various complex diseases. He works with more than 400 scientists from 100+ top ranked organizations across 40+ countries and has 220+ publications and a branded editor for 10+ cutting-edge omics related reference books. He is a reviewer of journals from Nature publications, Elsevier and AACR Journals, CMAJ, NAR, Molecular Medicine, Gene Therapy, BMC Series, Bioinformatics, PLOS etc. Due to his significant contribution in the field; he has been recognized by Who's Who in the World and Limca Book of Records. Dr. Vasco Azevedo is a full professor at the Department of Genetics, Ecology, and Evolution, Institute of Biological Sciences, Federal University of Minas Gerais, Brazil. He is a CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico) researcher 1A, member of the Brazilian Academy of Sciences, Commander of the Order of Scientific Merit of the MCTI of the genetics advisory committee and the public policy working group on biotechnology and genetic resources of COBRG/CNPq, coordinator of the Associated International Laboratory Bactinfl from INRAE and UFMG, and vice-president of the Brazilian Association of Bioinformatics and Computational Biology. He holds a degree in veterinary medicine from the School of Veterinary Medicine of the Federal University of Bahia (1986), a master's degree (1989), a doctorate (1993) in the genetics of microorganisms from the Institut National Agronomique Paris Grignon, and a doctorate in bioinformatics from UFMG (2017). He did his postdoctorate work with the Department of Microbiology, School of Medicine, University of Pennsylvania, United States (1994). He was a professor at the Institute of Biomedical Sciences of the University of São Paulo (2004). He is an expert in genetics and bioinformatics and his work mainly focuses on genomics, transcriptomics, proteomics, metabolomics, vaccine development, diagnostics, and the development of next generation probiotics. He has more than 600 scientific publications, 14 books, and 60 chapters as well as 12 patents.